Therefore, we performed this real-world study to evaluate the efficacy and safety of anti-PD1 plus RT versus TACE plus sorafenib in the treatment of advanced HCC, and seek a new approach for the treatment of advanced HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.